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Research
Altera tions in fetal programming in response 
to an adverse fetal environment may contrib-
ute to the development of metabolic syndrome 
(Gluckman and Hanson 2004). Components 
of the metabolic syndrome, such as eleva ted 
tri glyce rides and reduced high-density lipo-
protein choles terol (HDL), are known risk 
factors for cardiovascular disease and diabetes 
(Alberti et al. 2009). Recent findings from a 
longitudinal study suggest that maternal smok-
ing during pregnancy may play a role in the 
development of metabolic altera tions in off-
spring during childhood (Huang et al. 2007). 
However, whether in utero exposure to tobacco 
smoke is associa ted with metabolic altera tions 
during adulthood is uncertain (Power et al. 
2010) and the available epidemio logic data are 
insufficient. Previous studies, however, have 
reported an associa tion of in utero exposure 
to tobacco smoke with choles terol (Jaddoe 
et al. 2008; Wen et al. 2010) and carotid wall 
thickening during adulthood (Geerts et al. 
2008). To our knowledge, other metabolic 
risk factors, such as eleva ted apolipoprotein B 
(apoB) and C-reactive protein (CRP), have not 
been studied in rela tion to in utero exposure 
to tobacco smoke. Eleva ted tri glyce rides and 
reduced HDL (i.e., atherogenic dyslipidemia) 
are usually accompanied by eleva ted apoB; 
CRP is a marker of inflamma tion that tends 
to be eleva ted in people with atherosclerotic 
conditions and metabolic syndrome (Grundy 
et al. 2004).
The purpose of the present study was to 
evaluate the associa tion of in utero exposure 
to maternal tobacco smoke (i.e., exposure 
occurred 18–44 years earlier for women in 
the present analy sis) with altera tions in plasma 
lipids that are compatible with metabolic syn-
drome in adulthood. We also evalua ted the 
associa tion of in utero exposure to tobacco 
smoke with low-density lipoprotein choles terol 
(LDL), total choles terol, apoB, and CRP.
Methods
This study was based on the Norwegian 
Mother and Child Cohort Study (MoBa), con-
ducted by the Norwegian Institute of Public 
Health (Oslo, Norway) (Magnus et al. 2006). 
MoBa is a cohort based on 108,000 pregnan-
cies from 90,700 women enrolled from 1999 
to 2008. The majority of all pregnant women 
in Norway were invited to participate, and 
38.5% of invited women participa ted in the 
study. Participants were recruited with a mailed 
invita tion before a routine ultrasound examina-
tion offered to all pregnant women in Norway 
at 17–18 weeks of gesta tion (Norwegian 
Institute of Public Health 2007). The study 
was approved by the Regional Committee for 
Medical Research Ethics and the Norwegian 
Data Inspectorate (Oslo, Norway). Informed 
consent was provided by each participant. The 
present study is based on version 4.301 of the 
quality-assured data files released for research 
in December 2009. At enrollment, partici-
pants were asked to give a plasma specimen 
(median, 18 weeks of gesta tion; 25th and 75th 
percentiles, 17 and 19 weeks, respectively) 
and to complete a questionnaire about demo-
graphic characteristics, reproductive health, 
disease and medica tion history, lifestyle, and 
socio economic status. The present analy sis was 
based on a sub sample of 950 women whose 
plasma specimens were analyzed for lipids, 
apoB, and CRP for a case–base (Kupper et al. 
1975) study on sub fecundity (Whitworth et al. 
2012). For the case–base study, eligibility was 
restricted to all participants enrolled in 2003 
and 2004 who delivered a live-born child, pro-
vided a plasma specimen, and reported their 
time-to-pregnancy (n = 8,120). Cases (n = 400) 
were selected at random among eligible 
women who were sub fecund (i.e., with a time-
to-pregnancy of > 12 months; n = 839); the 
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Background: Recent findings suggest that maternal smoking during pregnancy may play a role 
in the development of metabolic altera tions in offspring during childhood. However, whether such 
exposure increases the risk of developing similar metabolic altera tions during adulthood is uncertain.
oBjective: We evalua ted the associa tion of in utero exposure to maternal tobacco smoke with 
plasma lipids, apolipoprotein B (apoB), and C-reactive protein (CRP) in adulthood.
Methods: The study was based on a sub sample of the Norwegian Mother and Child Cohort 
Study (MoBa) and included 479 pregnant women with plasma lipids, apoB, and CRP measure-
ments. Informa tion on in utero exposure to tobacco smoke, personal smoking, and other factors 
were obtained from the women by a self-completed questionnaire at enrollment, at approximately 
17 weeks of gesta tion.
results: Women exposed to tobacco smoke in utero had higher tri glyce rides [10.7% higher; 
95% confidence interval (CI): 3.9, 17.9] and lower high-density lipoprotein choles terol (HDL) 
(–1.9 mg/dL; 95% CI: –4.3, 0.5) compared with unexposed women, after adjusting for age, physi-
cal activity, educa tion, personal smoking, and current body mass index (BMI). Exposed women 
were also more likely to have tri glyce rides ≥ 200 mg/dL [adjusted odds ratio (aOR) = 2.5; 95% CI: 
1.3, 5.1] and HDL < 50 mg/dL (aOR = 2.3; 95% CI: 1.1, 5.0). Low-density lipoprotein choles terol, 
total choles terol, and apoB were not associa ted with the exposure. CRP was increased among exposed 
women; however, after adjustment for BMI, the associa tion was completely attenua ted.
conclusions: In this popula tion, in utero exposure to tobacco smoke was associa ted with high tri-
glyce rides and low HDL in adulthood, 18–44 years after exposure.
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base sample (n = 550) was selected at random 
from all eligible women regardless of sub-
fecundity status.
Assessment of in utero tobacco smoke. 
Women’s exposure to tobacco smoke in utero 
was ascertained on the baseline questionnaire. 
Women were asked “Did your mother smoke 
when she was pregnant with you?” Those who 
answered “yes” were classified as having been 
exposed to tobacco smoke in utero; those who 
responded “no” were considered unexposed. 
For women who participa ted with more than 
one pregnancy in the MoBa cohort, the con-
sistency of answers across pregnancies was 
verified. In general, if the woman gave two dif-
ferent answers in two consecutive pregnancies 
(e.g., yes/no; no/yes; no/don’t know; yes/don’t 
know), the response was considered incon-
sistent, and the subject was excluded from 
the analy sis. However, if the first answer was 
“Don’t know” and later she gave a different 
answer (yes or no), we used the latter under 
the assumption that the woman had asked her 
mother about her exposure in utero. Analy ses of 
data from the MoBa cohort support the valid-
ity and reproducibility of self- reported in utero 
exposure to tobacco smoke among MoBa par-
ticipants (Cupul-Uicab et al. 2011a, 2011b). 
Women were not asked about cigarette smoke 
exposure during childhood.
Plasma measurements. At enrollment, 
women provided a nonfasting blood speci-
men collected in EDTA tubes; the samples 
were shipped at ambient temperature from 
the collection site to Oslo where plasma was 
extracted and stored at –80° C (the majority of 
the samples were received the day after collec-
tion) (Ronningen et al. 2006). For the present 
study, we used the plasma specimens provided 
by the women at enrollment. Although some 
women participa ted with multi ple pregnan-
cies in MoBa, women could contribute with 
only one pregnancy in the present analy sis. 
Tri glyce rides, total choles terol, apoB, CRP, 
HDL, and LDL were determined in plasma 
specimens with an Olympus AU400e Clinical 
Chemistry Analyzer (Olympus America Inc., 
Irvin, TX, USA) using reagents for tri glyce-
rides and choles terol from Beckman Coulter 
(Brea, CA, USA) and reagents for the others 
from Genzyme Diagnostics (Framingham, 
MA, USA). Quantitative measurement of 
LDL was done with a direct enzymatic method 
(N-geneous® LDL-ST choles terol reagent). 
CRP was expressed in milligrams per liter and 
the other clinical chemistries were expressed 
in milligrams per deciliter. The within- and 
between-batch coefficients of varia tion (CV) of 
the analytical method were < 5% for all clinical 
chemistries, except for the between-batch CV 
for tri glyce rides (CV 6.3%).
Statistical analy sis. For the present analysis, 
women from the case–base study (n = 950) 
were excluded if they had missing data on 
body mass index (BMI), educa tion, or clinical 
chemistries (n = 8). In addition, women 
were excluded if, for in utero tobacco smoke, 
there was unknown exposure (n = 112) or 
inconsistent answers (n = 7) (see above). After 
all the exclusions, a total of 823 women were 
included in the analy sis (base sample, n = 479).
The associa tions of in utero exposure to 
tobacco smoke with levels of tri glyce rides, 
HDL, LDL, total choles terol, apoB, and CRP 
were assessed separately. The main analy sis 
was restricted to women from the base sample 
(selected without regard to sub fecundity 
status). We also conducted an analy sis that 
included all women from the MoBa sub sample 
using weighted linear regression to account 
for the case–base sampling (Richardson et al. 
2007). The weights were the inverse of the 
sampling probabilities for the original case–
base study. Tri glyce rides and CRP had skewed 
distributions and therefore were natural-
logarithm transformed before modeling; 
their corresponding coefficients represent the 
percent difference in geometric mean values 
for the exposed compared with the unexposed 
groups. For some of the outcomes, we also 
assessed whether clinically relevant altera tions 
in levels were associa ted with in utero exposure 
to tobacco smoke using logistic regression. 
We used previously recommended cut points 
to define high tri glyce rides (≥ 200 mg/dL), 
low HDL (< 50 mg/dL for females), high 
total choles terol (≥ 240 mg/dL), and high 
CRP (≥ 8 mg/L) levels [Na tional Choles terol 
Educa tion Program (NCEP) 2001; Pitiphat 
et al. 2005].
All models included in utero tobacco 
smoke as the main exposure and were adjusted 
for woman’s age (years), educa tion (≤ high 
school vs. > high school), and physical activity 
[times a week that the woman was engaged 
in activities such as brisk walking, running/
jogging/orienteering, bicycling, gymnastics, 
aerobics, dancing, skiing, or swimming (none, 
< 4, or ≥ 4 times a week)]. We use directed 
acyclic graphs (DAGs) to select this set of 
a priori varia bles (Greenland et al. 1999). 
Although the minimal sufficient set of varia-
bles to adjust for confounding did not include 
educa tion, we choose to adjust for each 
partici pant’s educa tion as a proxy indicator 
of her mother’s educa tion and socio economic 
status [see Supplemental Material, Figure S1 
(http://dx.doi.org/10.1289/ehp.1104563)]. 
Participants’ individual annual income was 
not selected a priori because of its correla tion 
with educa tion (Spearman r = 0.43, p < 0.01) 
and because the exposure and outcomes had 
stronger correla tions with educa tion than with 
income. Informa tion on the educa tion, socio-
economic status, and lifestyle habits of partici-
pants’ mothers was not ascertained in MoBa. 
Additional varia bles that were associa ted 
with at least one of the outcomes in bivariate 
analyses (p ≤ 0.20) were assessed as potential 
confounders [i.e., income, parity, and alcohol 
consumption (no, yes)] using the change in 
estimate method, starting with all varia bles in 
the models with deletion of one by one in a 
stepwise manner (Greenland 1989). None of 
the tested varia bles caused a change ≥ 10% in 
the coefficient for in utero smoking, thus we 
did not adjust for them. Participants’ personal 
smoking, BMI [weight (in kilograms) ÷ height 
(in meters squared)], and birth weight (in kilo-
grams) were potential intermediate varia bles 
that were included in selected models. BMI 
was entered as a continuous variable in the 
models because the results were comparable 
to those obtained using four cate gories. The 
effect of adjusting for birth weight was evalua-
ted among the subset of women born in 1967 
or later [when the Medical Birth Registry 
of Norway (Bergen, Norway) was estab-
lished] with available birth weight [88.8% 
of 752 (89% of 446 for the base sample)]. 
Multiplicative interactions of in utero expo-
sure to tobacco smoke (yes/no) with personal 
smoking (yes/no), BMI, and birth weight were 
tested in linear regression models but are not 
presented because the p-values for all interac-
tion terms were > 0.15. We also estima ted 
associa tions of in utero exposure to tobacco 
smoke (yes/no) with the outcomes in the 
absence or presence of overweight and obesity 
(BMI < 25 and ≥ 25 kg/m2, respectively) to 
assess departures from additive effects (Hosmer 
and Lemeshow 1992). However, numbers 
were too sparse to conduct similar analy ses for 
smoking and birth weight.
We conducted a number of sensitiv-
ity analy ses to assess the robustness of our 
results. We added the participant’s individual 
income to models in addition to educa tion 
because adjusting for both varia bles might 
be a more effective means of reducing con-
founding due to socio economic disadvantages 
throughout the participant’s life. We also 
estima ted associa tions adjusted for age and 
physical activity only, the minimal sufficient 
set of covariates based on the DAG. Because 
lipid levels can vary throughout pregnancy 
(Vahratian et al. 2010) and plasma specimens 
were not provided at the same week of gesta-
tion for all women, the models were further 
adjusted for gesta tional week at blood draw.
In additional sensitivity analy sis, multi ple 
imputa tion by chained equa tions (van Buuren 
et al. 1999) was performed in the complete 
sample (i.e., 950 subjects from the original 
case–base study) to impute values for any vari-
able with missing data. For the imputa tion 
procedure, we included all clinical chemistries 
(tri glyce rides and CRP entered as natural loga-
rithm), in utero exposure to tobacco smoke, 
all characteristics listed in Table 1, and BMI 
before pregnancy, weight and gesta tional age 
at birth, year of birth, year of enrollment, and 
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age of the participant’s mother at delivery. A 
total of 10 imputed data sets were genera ted 
using 20 cycles per imputa tion (van Buuren 
et al. 1999), and analy ses were repea ted using 
the imputed data. All analy ses were done using 
Stata (Stata Statistical Software, release 10.1; 
StataCorp, College Sta tion, TX, USA).
Results
The prevalence of in utero exposure to tobacco 
smoke among women in the base sample was 
> 35% among those with less than a college 
educa tion, a lower income, a BMI ≥ 30, who 
smoked more as adults, and who reported no 
physical activity (Table 1). Exposure preva-
lences according to participant characteris-
tics were similar among all 823 women (data 
not shown). Among women from the base 
sample, 7.9% had high tri glyce rides, 6.9% 
had low HDL, 20.3% had high choles terol, 
and 22.1% had high CRP, with similar 
prevalences among sub fecund MoBa partici-
pants [see Supplemental Material, Table S1 
(http://dx.doi.org/10.1289/ehp.1104563)]. 
Compared to sub fecund women, those from 
the base sample tended to be younger, and a 
higher proportion of them were college educa-
ted, had a previous pregnancy, had a BMI of 
< 25, and were nonsmokers (see Supplemental 
Material, Table S1). The ranges of lipids, 
apoB, and CRP measured in our sample (see 
Supplemental Material, Table S2) were com-
parable to reference levels for pregnant women 
in other popula tions (Klajnbard et al. 2010; 
Larsson et al. 2008).
Compared with unexposed women, those 
exposed to tobacco smoke in utero had higher 
median levels of tri glyce rides and CRP, and 
lower mean HDL (Table 2). After adjusting for 
age, physical activity, and educa tion, significant 
associa tions with tri glyce rides [13.4% higher; 
95% confidence interval (CI): 6.4, 20.9] and 
HDL (2.6 mg/dL lower; 95% CI: –5.0, –0.2) 
remained. Associa tions with all outcomes were 
similar after additional adjustment for personal 
smoking, but were attenua ted after adjusting 
for BMI (Table 3). Average values of LDL, 
total choles terol, and apoB tended to be higher 
among women exposed to tobacco smoke 
in utero, but the estimates were imprecise. 
The positive associa tion of CRP with expo-
sure to tobacco smoke in utero was still evi-
dent (though non significant) after adjusting for 
age, physical activity, and educa tion (16.3% 
higher in the exposed vs. unexposed women; 
95% CI: –2.6, 39.0), but was close to the null 
after adjusting for BMI (2.7% higher; 95% 
CI: –12.7, 20.9) (Table 3). When we analyzed 
the data from all women using weighted linear 
regression, in utero tobacco smoke exposure 
remained associa ted with tri glyce rides (12.1% 
higher in the exposed women; 95% CI: 5.5, 
19.2), HDL (2.3 mg/dL lower; 95% CI: –4.5, 
–0.1), and CRP (14.7% higher; 95% CI: 
–1.4, 33.5); estimates for LDL (3.3 mg/dL 
higher; 95% CI: –2.5, 9.1), total choles terol 
(2.3 mg/dL higher; 95% CI: –4.5, 9.1), and 
apoB (2.9 mg/dL higher; 95% CI: –1.5, 7.2) 
were similar to those from the base sample. 
After adjusting for BMI, the estimates were 
again attenua ted, but were consistent with 
those from the base sample; in utero exposure 
to tobacco smoke remained associa ted with 
tri glyce rides (9.4% higher in the exposed vs. 
unexposed women; 95% CI: 3.1, 16.1) and 
HDL (1.7 mg/dL lower; 95% CI: –3.9, 0.6), 
but not with CRP (2.1% higher; 95% CI: 
–10.9, 17.1).
Among 397 women in the base sample 
with known birth weight (Table 4), tri glyc-
erides remained higher and HDL lower among 
exposed compared with unexposed women 
before and after adjusting for birth weight 
(in addition to age, educa tion, BMI, personal 
smoking, and physical activity), and when the 
analy sis was restricted to 381 women born at 
term (i.e., gesta tional age ≥ 37 weeks). Other 
lipids, apoB, and CRP were again unrela ted to 
in utero exposure to tobacco smoke (Table 4). 
Associa tions were similar after adjusting 
for birth weight among all women (data 
not shown).
Compared with unexposed women, 
women exposed to tobacco smoke in utero were 
more likely to have tri glyce rides ≥ 200 mg/dL 
[adjusted OR (aOR) = 2.8; 95% CI: 1.4, 5.7], 
HDL < 50 mg/dL (aOR = 2.4; 95% CI: 
Table 1. Characteristics of women from the MoBa 
base sample at enrollment according to self-
 reported in utero exposure to tobacco smoke.
Characteristic  n (%) p-Valuea
All women 479 (28.0)
Age (years) 0.07
< 25 43 (27.9)
25–29 183 (34.4)
30–34 179 (21.8)
≥ 35 74 (27.0)
Educa tion < 0.01
< High school 32 (37.5)
High school 141 (39.0)
College 214 (22.9)
> College 92 (19.6)
Incomeb ($US) 0.07
< 30,847 119 (36.1)
30,847–46,269 200 (27.5)
46,270–61,693 115 (24.3)




≥ 2 86 (30.2)
BMI (kg/m2) < 0.01
< 25.0 253 (22.9)
25.0 to < 30.0 161 (28.6)
≥ 30.0 65 (46.2)
Smoking (cigarettes/day) 0.02
Nonsmoker 378 (25.7)
< 10 87 (33.3)
≥ 10 14 (57.1)
Alcohol drinking 0.77
No (nondrinker) 362 (27.3)
Yes (drinker) 73 (31.5)
Missing 44 (27.3)
Physical activity (times/week) 0.07
None 99 (38.4)
< 4.0 261 (26.1)
4.0 to < 7.5 89 (24.7)
≥ 7.5 30 (20.0)
ap-Values are from Pearson’s chi-square test comparing 
exposed and unexposed across cate gories of each 
variable. bIndividual annual income.
Table 2. Plasma lipids and apoB (mg/dL) and CRP (mg/L) by in utero exposure to tobacco smoke (no/yes) 
among women from the base sample at enrollment (n = 479).
Plasma level No (n = 345) Yes (n = 134) p-Valuea
Tri glyce rides 117.2 (47.0) 135.7 (71.0) < 0.01
HDL 68.4 ± 11.6 65.3 ± 12.7 0.01
LDL 126.5 ± 29.4 130.4 ± 32.4 0.20
Total choles terol 212.8 ± 33.7 215.2 ± 38.5 0.50
ApoB 99.7 ± 21.7 103.4 ± 24.5 0.11
CRP (mg/L) 4.0 (4.5) 5.0 (5.4) 0.01
Plasma levels are presented as means ± SD or geometric means (interquartile range).
ap-Values are from unadjusted linear regressions, except for tri glyce rides and CRP; two-sample Wilcoxon rank–sum 
(Mann–Whitney U) test for equality- of-medians was used for tri glyce rides and CRP.
Table 3. Estima ted associa tions [bs (95% CIs)] of in utero exposure to tobacco smoke with lipids, apoB, 










Tri glyce rides 15.8 (8.7, 23.4) 13.4 (6.4, 20.9) 13.4 (6.4, 21.0) 10.6 (3.8, 17.8) 10.7 (3.9, 17.9)
HDL –3.2 (–5.5, –0.8) –2.6 (–5.0, –0.2) –2.5 (–4.9, –0.1) –2.0 (–4.4, 0.4) –1.9 (–4.3, 0.5)
LDL 3.9 (–2.1, 10.0) 3.3 (–2.9, 9.4) 3.2 (–3.0, 9.4) 2.8 (–3.4, 9.1) 2.8 (–3.5, 9.1)
Total choles terol 2.4 (–4.6, 9.4) 2.1 (–5.1, 9.2) 2.3 (–4.9, 9.4) 1.9 (–5.3, 9.2) 2.1 (–5.2, 9.3)
ApoB 3.7 (–0.8, 8.2) 2.8 (–1.7, 7.4) 2.9 (–1.7, 7.5) 2.2 (–2.4, 6.8) 2.3 (–2.4, 6.9)
CRP 24.6 (4.5, 48.5) 16.3 (–2.6, 39.0) 15.9 (–3.0, 38.5) 2.7 (–12.7, 20.9) 2.9 (–12.6, 21.1)
Associa tions are expressed as the percent difference in the geometric mean for logn-transformed outcomes (mg/dL 
tri glyce rides and mg/L CRP) or the difference in mean values (mg/dL of HDL, LDL, total choles terol, and ApoB) in the 
exposed compared with the unexposed group.
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1.1, 5.1), and CRP ≥ 8 mg/L (aOR = 1.6; 95% 
CI: 1.0, 2.6); the odds of having choles terol 
≥ 240 mg/dL was slightly higher (aOR = 1.4, 
95% CI: 0.9, 2.3) among exposed women 
(Table 5). After additional adjustment for BMI, 
the associa tion of in utero exposure to tobacco 
with high tri glyce rides and low HDL remained 
statistically significant, but that was not the 
case for CRP. In the analy sis that included all 
women, the associa tions were consistent with 
those from the base sample (Table 5).
Compared with women who were unex-
posed and had a BMI of < 25 (kg/m2), women 
exposed to tobacco smoke in utero tended to 
have higher odds of high tri glyce rides, low 
HDL, and high total choles terol regardless 
of their BMI (< 25 or ≥ 25), whereas women 
with BMI ≥ 25 tended to have higher odds 
of high CRP regardless of their exposure; 
the confidence intervals, however, were wide 
(Table 6). Among unexposed women, higher 
BMI (≥ 25 kg/m2) was also associa ted with 
higher odds of having high tri glyce rides, low 
HDL, and high total choles terol.
Estimates from models adjusted for par-
ticipant’s age and physical activity only (the 
minimum sufficient adjustment set based on 
a DAG), fell between unadjusted estimates 
and estimates adjusted for age, educa tion, and 
physical activity [tri glyce rides: 15.3% higher in 
the exposed vs. unexposed women (95% CI: 
8.1, 22.9); HDL: 2.9 mg/dL lower (95% CI: 
–5.2, –0.5); and CRP: 20.8% higher (95% 
CI: 1.2, 44.1)]. The results from Tables 3 and 
5 remained essentially the same after addi-
tional adjustment for gesta tional week at 
blood draw and income (data not shown). The 
results obtained from the multi ple imputa tion 
analy ses were comparable to those observed 
based on complete data (data not shown). 
Among women selected as cases (i.e., sub-
fecund), in utero exposure to tobacco smoke 
was not associa ted with any outcome before or 
after adjusting for BMI; after BMI was added 
to the models, the signs of the estimates for tri-
glyce rides, HDL, and CRP were in the direc-
tion opposite to those shown before adjusting 
for BMI [see Supplemental Material, Table S3 
(http://dx.doi.org/10.1289/ehp.1104563)].
Discussion
In the present study, exposure to tobacco 
smoke in utero was associa ted with higher tri-
glyce rides and lower HDL during adulthood 
in a popula tion of pregnant women. These 
adverse altera tions in plasma lipids are compat-
ible with the metabolic syndrome, and there-
fore of clinical relevance. The odds of having 
eleva ted tri glyce rides or low HDL levels were 
doubled among women exposed to tobacco 
smoke in utero as compared with unexposed 
women. Plasma LDL, total choles terol, and 
apoB were not associa ted with the exposure 
in the adjusted analy ses. Women exposed to 
tobacco smoke in utero also tended to have 
higher CRP, although this associa tion was 
explained by the associa tion of the  exposure 
with BMI.
An adverse lipid profile early in life has 
been reported among children and adoles-
cents exposed to tobacco smoke in utero as 
well as among those exposed to parental smok-
ing during childhood (Huang et al. 2007; 
Metsios et al. 2011). Among 8,815 men and 
women (approximately 45 years of age) from 
the 1958 British birth cohort, in utero expo-
sure to tobacco smoke was associa ted with 
high tri glyce rides and low HDL, although 
the latter was limi ted to women (Power 
et al. 2010). However, after accounting for 
life-time covariates and potential mediators 
(e.g., birth weight, gesta tional age, breast-
feeding, educa tion, physi cal activity, personal 
smoking) simultaneously in the analy sis, these 
associations were weaker and no longer statisti-
cally signifi cant (Power et al. 2010). Similarly, 
among 3,824 men and women (approxi-
mately 23 years of age) from a Brazilian birth 
cohort, in utero exposure to tobacco smoke was 
associa ted with low HDL in women but not in 
men; this associa tion was also weakened and 
no longer statistically significant after account-
ing for confounders and potential mediators 
(e.g., birth weight, physical activity, personal 
smoking, BMI, waist circumference) (Horta 
et al. 2011). In the present study, the positive 
associa tion between tri glycerides and in utero 
exposure to tobacco smoke was consistent 
and remained after all adjustments; it was also 
supported by our analy sis using the recom-
mended clinical cut point used to define high 
tri glyce rides (≥ 200 mg/dL) (NCEP 2001). As 
reported in previous studies (Horta et al. 2011; 
Power et al. 2010), the associa tion between 
Table 5. Adjusteda ORs (95% CIs) for selected lipids and CRP by in utero exposure to tobacco smoke 
among MoBa participants.
Outcome









Tri glyce rides ≥ 200 mg/dL 38 2.8 (1.4, 5.7) 2.5 (1.3, 5.1) 72 2.5 (1.3, 4.7) 2.2 (1.2, 4.3)
HDL < 50 mg/dL 33 2.4 (1.1, 5.1) 2.3 (1.1, 5.0) 61 2.1 (1.1, 4.0) 2.0 (1.0, 4.1)
Total choles terol ≥ 240 mg/dL 97 1.4 (0.9, 2.3) 1.4 (0.8, 2.3) 159 1.4 (0.9, 2.2) 1.4 (0.9, 2.2)
CRP ≥ 8 mg/L 106 1.6 (1.0, 2.6) 1.2 (0.7, 2.1) 197 1.6 (1.1, 2.5) 1.2 (0.8, 2.0)
aAll models were adjusted for age, educa tion, physical activity, and smoking. bLogistic regression models weighted for 
sampling probability. cNumber of participants classified as having the outcome.
Table 4. Adjusteda coefficients [bs (95% CIs)] for lipids, apoB, and CRP by in utero exposure to tobacco 
smoke among women from the MoBa base sample with available birth weight.
Outcome
All women with available birth weight (n = 397)








Tri glyce rides 11.1 (3.6, 19.1) 9.5 (2.1, 17.4) 10.2 (2.6, 18.5)
HDL –3.2 (–5.9, –0.6) –3.6 (–6.3, –0.9) –4.2 (–7.0, –1.4)
LDL 0.9 (–5.6, 7.5) 0.0 (–6.6, 6.6) –1.8 (–8.6, 5.1)
Total choles terol –0.7 (–8.3, 6.8) –2.1 (–9.7, 5.5) –3.6 (–11.5, 4.3)
ApoB 1.0 (–3.8, 5.8) 0.5 (–4.3, 5.4) –0.2 (–5.2, 4.8)
CRP 5.0 (–12.3, 25.7) 3.4 (–13.9, 24.1) 0.4 (–16.7, 21.0)
Associa tions are expressed as the percent difference in the geometric mean for logn-transformed outcomes (mg/dL 
tri glyce rides and mg/L CRP) or the difference in mean values (mg/dL of HDL, LDL, total choles terol, and ApoB) in the 
exposed compared with the unexposed group.
aAll models were adjusted for age, educa tion, physical activity, smoking, and BMI at blood draw. bGesta tional age 
≥ 37 weeks. cAdditionally adjusted for participant’s gesta tional age at birth.
Table 6. Adjusteda ORs (95% CIs) for selected clinical chemistries by in utero exposure to tobacco smoke 
and BMI (< 25 and ≥ 25 kg/m2) among adult women.
In utero exposure to 
tobacco smoke/BMI n









Unexposed/BMI < 25 195 1.0 1.0 1.0 1.0
Unexposed/BMI ≥ 25 150 3.5 (1.2, 10.3) 2.5 (0.9, 6.9) 1.5 (0.9, 2.7) 4.0 (2.2, 7.1)
Exposed/BMI < 25 58 4.7 (1.4, 15.7) 4.4 (1.4, 14.4) 1.7 (0.8, 3.5) 1.1 (0.4, 2.8)
Exposed/BMI ≥ 25 76 6.9 (2.3, 20.6) 3.5 (1.2, 10.7) 1.7 (0.9, 3.4) 6.1 (3.2, 12.0)
All womenb 823
Unexposed BMI < 25 318 1.0 1.0 1.0 1.0
Unexposed BMI ≥ 25 265 3.1 (1.2, 7.8) 2.5 (1.0, 6.1) 1.5 (0.9, 2.4) 4.0 (2.4, 6.9)
Exposed BMI < 25 98 3.8 (1.4, 10.8) 3.8 (1.3, 11.1) 1.7 (0.9, 3.2) 1.2 (0.5, 2.6)
Exposed BMI ≥ 25 142 5.5 (2.1, 14.0) 3.2 (1.2, 8.2) 1.7 (0.9, 3.1) 6.1 (3.3, 11.2)
aAll models were adjusted for age, educa tion, physical activity, and smoking. bLogistic regression models weighted for 
sampling probability.
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reduced HDL and exposure to tobacco smoke 
in utero may not be independent of adult BMI; 
however, when using the recommended cut 
point for defining low HDL (for women, 
< 50 mg/dL) (NCEP 2001) the odds were 
doubled among exposed compared with unex-
posed women.
Our results differ from two recent studies 
where in utero exposure to tobacco smoke was 
associa ted with total choles terol in adulthood 
(Jaddoe et al. 2008; Wen et al. 2010). We 
observed a positive associa tion between in utero 
exposure to tobacco smoke and total choles-
terol, but associa tions were weak and estimates 
were imprecise. Jaddoe et al. (2008) reported 
that the associa tion of in utero smoking with 
total choles terol was stronger among partici-
pants with moderate overweight compared to 
those with normal BMI. In our data, there 
was no signifi cant departure from additive or 
multiplicative joint effects of BMI and in utero 
exposure to tobacco smoke. In addition, the 
odds of having high choles terol among women 
exposed to tobacco smoke in utero were similar 
when the BMI was < 25 and ≥ 25 kg/m2.
Whether in utero exposure to tobacco 
smoke (or parental smoking during childhood 
as a surrogate of in utero exposure) is a risk fac-
tor for metabolic syndrome during adulthood 
remains unclear (Hunt et al. 2006; Power 
et al. 2010). We did not have data on blood 
pressure, fasting glucose, or central obesity, 
which are also components of the metabolic 
syndrome in addition to plasma tri glyce rides 
and HDL (Alberti et al. 2009). However, a 
higher prevalence of hyper tension and obesity 
in rela tion to tobacco smoke in utero has been 
previously reported among 74,023 women 
enrolled in MoBa, which included some of 
the participants in the present analy sis (Cupul-
Uicab et al. 2012).
In animals, fetal exposure to nicotine 
at doses rele vant to humans (i.e., serum 
cotinine levels of 136–300 ng/mL as found 
among moderate to heavy smokers) results 
in long-term metabo lic altera tions in adult-
hood that are consistent with components of 
the metabo lic syndrome in humans (Bruin 
et al. 2010). In humans however, other less 
studied constituents of tobacco smoke such 
as carbon monoxide might also contribute to 
adverse lipid profiles (i.e., carbon monoxide 
is associated with fetal hypoxia, which can 
increase oxida tive stress and potentially alter 
lipid metabo lism in the fetus) (Chelchowska 
et al. 2011; Wen et al. 2010).
As in other observa tional studies, causal 
associa tions cannot be established with these 
data. It is possible that in utero exposure to 
tobacco smoke is acting as a marker of socio-
economic disadvantage during childhood, 
and the latter may be rela ted to a higher 
risk for adult disease (Donovan and Susser 
2011). Lifetime socio economic status of the 
participants was not available in MoBa. As 
shown in previous studies and in the present 
study, adjusting for factors such as BMI usu-
ally leads to weaker associa tions; however, the 
appropriateness of adjusting for risk factors 
that are affected by the exposure is debatable 
(Cole and Hernan 2002).
Estima ted effects of exposure in conjunction 
with BMI showed strong associa tions of in utero 
exposure to tobacco smoke with high tri glyce-
rides (aOR = 4.7; 95% CI: 1.4, 15.7) and 
reduced HDL (aOR = 4.4; 95% CI: 1.4, 14.4) 
among women with normal BMI (Table 6). 
The combined estimate was consistent with 
additive effects of BMI and exposure on tri-
glyce rides and HDL, but the statistical power 
of the study for evalua tion of inter action was 
limited. High BMI was associa ted with high 
CRP regardless of exposure, and the combined 
estimate suggests a weak associa tion between 
in utero exposure to tobacco smoke and high 
CRP among overweight or obese women.
Although exposure data were collected 
retro spectively, reported exposure to mater-
nal tobacco smoke in utero by the adult off-
spring has been shown to be valid (Simard 
et al. 2008); and previous analy ses from MoBa 
partici pants also supports the validity and 
reproducibility of self- reported exposure to 
tobacco smoke in utero (Cupul-Uicab et al. 
2011a, 2011b). An analy sis of data from multi-
ple popula tions indica ted that birth weight 
is 149 g lower, on average, in children whose 
mothers smoked during pregnancy com-
pared with children whose mothers did not 
smoke (Kramer 1987). The estima ted aver-
age 181-g reduction in birth weight associa ted 
with in utero exposure to tobacco smoke in 
a subset of 11,082 MoBa participants indi-
rectly supports the validity of self- reported 
in utero exposure (Cupul-Uicab et al. 2011b). 
The reproducibility of self- reported in utero 
exposure to tobacco smoke among MoBa 
participants who completed questionnaires 
for multi ple pregnancies was high (weighted 
κ = 0.80) (Cupul-Uicab et al. 2011b). The 
intensity of in utero exposure to tobacco smoke 
was not ascertained in MoBa; therefore we were 
unable to assess a dose–response rela tionship.
The prevalence of in utero exposure to 
tobacco smoke in the present study (28% in 
the base sample) was similar to that for the 
MoBa cohort as a whole (approximately 
27.8%), but the associa tion between in utero 
exposure to tobacco smoke and obesity was 
slightly stronger in the base sample (aOR = 2.0; 
95% CI: 1.10, 3.77) than in the full MoBa 
cohort (aOR = 1.53; 95% CI: 1.45, 1.61) 
(Cupul-Uicab et al. 2012). As expected, physi-
cal activity was associa ted with higher HDL 
and lower tri glyce rides, choles terol, and LDL 
in the present study (data not shown).
Among sub fecund women (i.e., with a 
time to pregnancy > 12 months), in utero 
exposure to tobacco smoke was not associa ted 
with lipid, apoB, or CRP levels. Sub fecund 
women are more likely to have conditions 
associa ted with lipid altera tions (e.g., poly-
cystic ovary syndrome) (Norman et al. 2007) 
that are probably stronger predictors of the 
outcomes than in utero exposure to tobacco 
smoke, which may explain the lack of associa-
tion among this subset of women.
In the present study, lipids were measured 
in nonfasting plasma specimens. Although 
tri glyce rides are known to be higher in the 
postprandial period, a recent prospective study 
among 26,509 women suggests that non-
fasting tri glyce rides may be a better predictor 
of cardiovascular events (Bansal et al. 2007). 
The impact of adjusting for recent food con-
sumption on associa tions between in utero 
exposure to tobacco smoke and components 
of the metabolic syndrome was negligible in 
the 1958 British cohort, a previous study that 
also measured lipids in nonfasting samples 
(Power et al. 2010). Because the cutoff points 
to define high tri glyce rides are based on fast-
ing levels of tri glyce rides, potential mis classifi-
ca tion of this outcome may be a concern; 
however, this might not be a concern for our 
analy sis based on the continuous outcome. 
Furthermore, our results may not be directly 
comparable to those from fasting subjects or 
from non-pregnant women, and they may 
not be generalizable to non-pregnant women. 
Whether or not metabolic syndrome is a 
real entity (Kahn et al. 2005), clearly hyper-
triglyceridemia is an independent risk factor 
for coronary heart disease (NCEP 2001).
Conclusion
Women exposed to tobacco smoke in utero 
were more likely to have high tri glyce rides and 
low HDL as adults. These adverse altera tions 
in plasma lipids are compatible with metabolic 
syndrome and may have implica tions for future 
cardiovascular disease among the exposed.
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